Is Embecta Corp (EMBC) overvalued? · P/E 12, rev $1.08B
Embecta Corp (EMBC) is a medical instruments & supplies company listed on US.
This page asks whether Embecta Corp (EMBC) looks expensive on cached numbers — not a short thesis.
Latest reported EMBC revenue for 2025-09-30 was $1.08B. Net income was $95.4M. Revenue was down 3.8% from 2024-09-30 to 2025-09-30. EMBC currently screens at market cap $609.6M and trailing P/E 11.7.
EMBC currently screens at market cap $609.6M and trailing P/E 11.7. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EMBC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EMBC stock page for the full model, not this heading.
Not investment advice.